rethinkPeptides Search
Menu
Research citation

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

Diabetes, obesity & metabolism, 24(1), 94-105

Citation

Wharton, Sean; Calanna, Salvatore; Davies, Melanie; Dicker, Dror; Goldman, Bryan; Lingvay, Ildiko; Mosenzon, Ofri; Rubino, Domenica M; Thomsen, Mette; Wadden, Thomas A; Pedersen, Sue D. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.. Diabetes, obesity & metabolism, 24(1), 94-105. https://doi.org/10.1111/dom.14551